¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26
±³À°ÀÏÀÚ : 2023-02-26
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
´ã´çÀÚ : ½ÅÀåÇÐȸ»ç¹«±¹
¿¬¶ôó : 02-3486-8736  
À̸ÞÀÏ : ksn@ksn.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 160,000¿ø      
ºñ°í BRC (ÀüÀÏ) + ARC (3/26):160,000 ¿ø, BRC (1ÀÏ) + ARC (3/26) 120,000 ¿ø BRC (1ÀÏ): 80,000 ¿ø, ¸¸65¼¼ ÀÌ»ó ȸ¿ø, Çлý:¸éÁ¦      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:00~09:30 Basic renal pathology and evaluation of primary glomerular disease   ±Ç±â¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 09:30~10:00 An update on the management of IgA nephropathy   °­¼®ÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:00~10:30 Immunoglobulin- and complement-mediated glomerular diseases with an MPGN pattern of injury  ¹Ú¼±Èñ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 10:30~11:00 Overview of the pathogenesis and treatment of ANCA-associated GN (ARC ¿¬°è °­ÀÇ)  È«À¯¾Æ(°¡Å縯ÀÇ´ë) 
È޽Ġ02-26  11:00~11:10 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:10~11:40 How to use SGLT2 inhibitor and GLP-1 receptor agonist in diabetic kidney disease (ARC ¿¬°è °­ÀÇ)  ±æÈ¿¿í(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 11:40~12:10 Pathophysiology of diabetic kidney disease  ¹®ÁÖ¿µ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 12:10~12:40 Optimal treatment of dyslipidemia in diabetic kidney disease   À¯ÅÂÇö(¿¬¼¼ÀÇ´ë) 
½Ä»ç 02-26  12:40~13:30 Lunch Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 13:30~14:00 Evaluation for resistant hypertension in advanced CKD patients  ÀÌÁ¤È¯(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:00~14:30 Treatment of osteoporosis in CKD  ±èÁ°æ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 14:30~15:00 Optimal management of anemia: EPO, iron, and new therapeutics  °í°­Áö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:00~15:30 Hypertension management in kidney transplant recipients  Á¤Á¾Ã¶(¼­¿ïÀÇ´ë) 
È޽Ġ02-26  15:30~15:40 Break  () 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 15:40~16:10 HDF vs. expanded hemodialysis (ARC ¿¬°è °­ÀÇ)  ÀÌ¿µ±â(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:10~16:40 Flow related complication of arteriovenous fistula (ARC ¿¬°è °­ÀÇ)  ¹ÚÈƼ®(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 02-26 ¸¶¸®¾ÆȦ 16:40~17:10 How should we change the PD prescription when adequacy targets are not met?  ±Ç¼ø±æ(ÃæºÏÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (2ÀÏÂ÷) : 2023-02-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ºû°íÀ»Àü³²´ëÇб³º´¿ø ·ù¸¶Æ¼½º³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2023-02-26
´ÙÀ½±Û ´ëÇѽÅÀåÇÐȸ Á¦16ȸ KSN-BRC (Board Review Course) (1ÀÏÂ÷) : 2023-02-25
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21153 ¼­¿ï ´ëÇÑ¿Ü»óÁßȯÀÚ¿Ü°úÇÐȸ Á¦50Â÷ Áý´ãȸ (Management of upper & lower GI bleeding) : 2024-07-13 0 0 2024-07-01
21152 ºÎ»ê ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ÇÏ°èÁý´ãȸ : 2024-07-11 0 0 2024-07-01
21151 ºÎ»ê ´ëÇѺñ´¢ÀÇÇÐȸ 311ȸ Çмú´ëȸ(Àü¸³¼± ¾Ï) : 2024-07-11 0 0 2024-07-01
21150 ºÎ»ê ´ëÇÑ°£ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2024-07-11 0 2 2024-07-01
21149 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ) KSMO 7¿ù ºÐ±âÁý´ãȸ : 2024-07-11 0 0 2024-07-01
21148 ÀÎõ Çѱ¹¿©ÀÚÀÇ»çȸ ÀÎõÁöȸ 7¿ù Çмú½ÉÆ÷Áö¾ö(Ä¡¸Å) : 2024-07-10 0 0 2024-07-01
21147 ¼­¿ï Á¦137ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Áý´ãȸ : 2024-07-10 0 0 2024-07-01
21146 ¿ï»ê ¿ï»ê À̺ñÀÎÈÄ°ú Çмú ¼¼¹Ì³ª : 2024-07-09 0 0 2024-07-01
21145 ´ëÀü ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ´ëÀüÃæûÁöȸ 7¿ù ¿¬¼ö°­Á : 2024-07-09 0 0 2024-07-01
21144 ¼­¿ï 2024 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦33Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-07-07 0 0 2024-07-01
21143 ´ëÀü 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ´ëÀüÃæûÁöȸ ¿¬¼ö°­Á : 2024-07-07 0 0 2024-07-01
21142 ¼­¿ï 2024³â Á¦11ȸ ´ëÇѳ²¼º°úÇÐȸ-´ëÇѺñ´¢ÀÇÇаúÀÇ»çȸ °øµ¿½ÉÆ÷Áö¾ö : 2024-07-07 0 0 2024-07-01
21141 ¿ï»ê ¿ï»ê´ëÇб³º´¿ø ½Å°æ¿Ü°ú ½ÉÆ÷Áö¿ò : 2024-07-06 0 1 2024-07-01
21140 ´ë±¸ Á¦7ȸ °æºÏ´ëÇб³ ¾È°úÇб³½Ç ½ÉÆ÷Áö¾ö : 2024-07-06 0 0 2024-07-01
21139 ¼­¿ï 2024 ´ëÇѵΰæºÎ¿Ü°úÇÐȸ ÃÊÀ½ÆÄ ¿öÅ©¼ó : 2024-07-06 0 0 2024-07-01
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷